An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy

An NRG Oncology/Gynecologic Oncology Group experience

Kate E. Oliver, William E. Brady, Michael Birrer, David M. Gershenson, Gini Fleming, Larry J. Copeland, Krishnansu Tewari, Peter A Argenta, Robert S. Mannel, Angeles Alvarez Secord, Jean Marie Stephan, David G. Mutch, Frederick B. Stehman, Franco M. Muggia, Peter G. Rose, Deborah K. Armstrong, Michael A. Bookman, Robert A. Burger, John H. Farley

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Purpose We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods We reviewed data from FIGO stage I–IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). Results There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I–II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR = 1.66 (1.43, 1.91; p < 0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR = 1.53 (1.33, 1.76; p < 0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p = 0.048). Conclusions This is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology.

Original languageEnglish (US)
Pages (from-to)243-249
Number of pages7
JournalGynecologic oncology
Volume147
Issue number2
DOIs
StatePublished - Nov 1 2017
Externally publishedYes

Fingerprint

Platinum
Ovarian Neoplasms
Disease-Free Survival
Carcinoma
Survival
Therapeutics
Histology
Ovarian epithelial cancer
Clinical Protocols
Paclitaxel
Proportional Hazards Models
Cell Survival
Observation

Keywords

  • Cancer
  • Clear cell
  • Histology
  • Ovarian
  • Survival

Cite this

An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy : An NRG Oncology/Gynecologic Oncology Group experience. / Oliver, Kate E.; Brady, William E.; Birrer, Michael; Gershenson, David M.; Fleming, Gini; Copeland, Larry J.; Tewari, Krishnansu; Argenta, Peter A; Mannel, Robert S.; Secord, Angeles Alvarez; Stephan, Jean Marie; Mutch, David G.; Stehman, Frederick B.; Muggia, Franco M.; Rose, Peter G.; Armstrong, Deborah K.; Bookman, Michael A.; Burger, Robert A.; Farley, John H.

In: Gynecologic oncology, Vol. 147, No. 2, 01.11.2017, p. 243-249.

Research output: Contribution to journalArticle

Oliver, KE, Brady, WE, Birrer, M, Gershenson, DM, Fleming, G, Copeland, LJ, Tewari, K, Argenta, PA, Mannel, RS, Secord, AA, Stephan, JM, Mutch, DG, Stehman, FB, Muggia, FM, Rose, PG, Armstrong, DK, Bookman, MA, Burger, RA & Farley, JH 2017, 'An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience', Gynecologic oncology, vol. 147, no. 2, pp. 243-249. https://doi.org/10.1016/j.ygyno.2017.08.004
Oliver, Kate E. ; Brady, William E. ; Birrer, Michael ; Gershenson, David M. ; Fleming, Gini ; Copeland, Larry J. ; Tewari, Krishnansu ; Argenta, Peter A ; Mannel, Robert S. ; Secord, Angeles Alvarez ; Stephan, Jean Marie ; Mutch, David G. ; Stehman, Frederick B. ; Muggia, Franco M. ; Rose, Peter G. ; Armstrong, Deborah K. ; Bookman, Michael A. ; Burger, Robert A. ; Farley, John H. / An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy : An NRG Oncology/Gynecologic Oncology Group experience. In: Gynecologic oncology. 2017 ; Vol. 147, No. 2. pp. 243-249.
@article{9735de9fdf1c4e9bba15edfdc558e719,
title = "An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy: An NRG Oncology/Gynecologic Oncology Group experience",
abstract = "Purpose We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods We reviewed data from FIGO stage I–IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). Results There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6{\%}) had OCCC, 7054 (74{\%}) had SOC, and 1933 (20{\%}) had other histologies and are not included further. In early stage (I–II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR = 1.66 (1.43, 1.91; p < 0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR = 1.53 (1.33, 1.76; p < 0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p = 0.048). Conclusions This is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology.",
keywords = "Cancer, Clear cell, Histology, Ovarian, Survival",
author = "Oliver, {Kate E.} and Brady, {William E.} and Michael Birrer and Gershenson, {David M.} and Gini Fleming and Copeland, {Larry J.} and Krishnansu Tewari and Argenta, {Peter A} and Mannel, {Robert S.} and Secord, {Angeles Alvarez} and Stephan, {Jean Marie} and Mutch, {David G.} and Stehman, {Frederick B.} and Muggia, {Franco M.} and Rose, {Peter G.} and Armstrong, {Deborah K.} and Bookman, {Michael A.} and Burger, {Robert A.} and Farley, {John H.}",
year = "2017",
month = "11",
day = "1",
doi = "10.1016/j.ygyno.2017.08.004",
language = "English (US)",
volume = "147",
pages = "243--249",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - An evaluation of progression free survival and overall survival of ovarian cancer patients with clear cell carcinoma versus serous carcinoma treated with platinum therapy

T2 - An NRG Oncology/Gynecologic Oncology Group experience

AU - Oliver, Kate E.

AU - Brady, William E.

AU - Birrer, Michael

AU - Gershenson, David M.

AU - Fleming, Gini

AU - Copeland, Larry J.

AU - Tewari, Krishnansu

AU - Argenta, Peter A

AU - Mannel, Robert S.

AU - Secord, Angeles Alvarez

AU - Stephan, Jean Marie

AU - Mutch, David G.

AU - Stehman, Frederick B.

AU - Muggia, Franco M.

AU - Rose, Peter G.

AU - Armstrong, Deborah K.

AU - Bookman, Michael A.

AU - Burger, Robert A.

AU - Farley, John H.

PY - 2017/11/1

Y1 - 2017/11/1

N2 - Purpose We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods We reviewed data from FIGO stage I–IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). Results There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I–II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR = 1.66 (1.43, 1.91; p < 0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR = 1.53 (1.33, 1.76; p < 0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p = 0.048). Conclusions This is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology.

AB - Purpose We examined disparities in prognosis between patients with ovarian clear cell carcinoma (OCCC) and serous epithelial ovarian cancer (SOC). Methods We reviewed data from FIGO stage I–IV epithelial ovarian cancer patients who participated in 12 prospective randomized GOG protocols. Proportional hazards models were used to compare progression-free survival (PFS) and overall survival (OS) by cell type (clear cell versus serous). Results There were 10,803 patients enrolled, 9531 were eligible, evaluable and treated with platinum, of whom 544 (6%) had OCCC, 7054 (74%) had SOC, and 1933 (20%) had other histologies and are not included further. In early stage (I–II) patients, PFS was significantly better in OCCC than in SOC patients. For late stage (III, IV) patients, OCCC had worse PFS and OS compared to SOC, OS HR = 1.66 (1.43, 1.91; p < 0.001). After adjusting for age and stratifying by protocol and treatment arm, stage, performance status, and race, OCCC had a significantly decreased OS, HR = 1.53 (1.33, 1.76; p < 0.001). In early stage cases, there was a significantly decreased treatment effect on PFS for consolidative therapy with weekly Paclitaxel versus observation in OCCC compared to SOC (p = 0.048). Conclusions This is one of the largest analyses to date of OCCC treated on multiple cooperative group trials. OCCC histology is more common than SOC in early stage disease. When adjusted for prognostic factors, in early stage patients, PFS was better for OCCC than for SOC; however, in late-stage patients, OCCC was significantly associated with decreased OS. Finally, treatment effect was influenced by histology.

KW - Cancer

KW - Clear cell

KW - Histology

KW - Ovarian

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=85028088990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85028088990&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2017.08.004

DO - 10.1016/j.ygyno.2017.08.004

M3 - Article

VL - 147

SP - 243

EP - 249

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -